CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$300.02
−0.04%Year over year
Reported trailing growth
- Revenue
- -0.7%
- EBITDA
- -58.3%
- EBIT
- +296.6%
- EPS
- —
- Free cash flow
- -35.9%
- Operating cash flow
- -26.1%
Forward estimates
Based on analyst estimates
- Revenue
- -1.1%
- EBITDA
- +465.0%
- EPS
- +361.1%
Three-year CAGR
- Revenue
- +0.3%
- EBITDA
- -25.3%
- EBIT
- -7.9%
- Net income
- —
- EPS
- —
- Free cash flow
- +20.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026